# Potassium and Related Disorders

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/potassium-and-related-disorders/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the management of hyperkalemia, particularly in patients with kidney diseases. It covers various aspects such as the use of renin-angiotensin-aldosterone system inhibitors, potassium homeostasis, and the effectiveness of treatments like sodium zirconium cyclosilicate and patiromer. Additionally, it explores the association of hyperkalemia with conditions like chronic kidney disease, heart failure, and gastrointestinal adverse events. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t12876 |
| Works | 253 |

## Topic papers all

Showing 15 of 253.

- [Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy/)
- [Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)](https://scholariq.org/papers/effects-of-enalapril-on-mortality-in-severe-congestive-heart-failure-results-of/)
- [Chronic Kidney Disease Diagnosis and Management](https://scholariq.org/papers/chronic-kidney-disease-diagnosis-and-management/)
- [Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction](https://scholariq.org/papers/effect-of-d-sotalol-on-mortality-in-patients-with-left-ventricular-dysfunction/)
- [Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-acute-decompensated-heart-failure/)
- [Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure](https://scholariq.org/papers/comparative-effects-of-low-and-high-doses-of-the-angiotensin-converting-enzyme/)
- [Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis](https://scholariq.org/papers/cardiovascular-and-kidney-outcomes-with-finerenone-in-patients-with-type-2/)
- [Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease](https://scholariq.org/papers/serum-phosphate-levels-and-mortality-risk-among-people-with-chronic-kidney/)
- [Independent Association between Acute Renal Failure and Mortality following Cardiac Surgery](https://scholariq.org/papers/independent-association-between-acute-renal-failure-and-mortality-following/)
- [The Use of Diuretics in Heart Failure with Congestion — A Position Statement from the Heart Failure Association of the European Society of Cardiology](https://scholariq.org/papers/the-use-of-diuretics-in-heart-failure-with-congestion-a-position-statement-from/)
- [Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999](https://scholariq.org/papers/chronic-kidney-disease-and-the-risk-for-cardiovascular-disease-renal-replacement/)
- [ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment](https://scholariq.org/papers/ispd-peritonitis-recommendations-2016-update-on-prevention-and-treatment/)
- [SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis](https://scholariq.org/papers/sglt2-inhibitors-for-the-prevention-of-kidney-failure-in-patients-with-type-2/)
- [Gastric Mucosal Defense and Cytoprotection: Bench to Bedside](https://scholariq.org/papers/gastric-mucosal-defense-and-cytoprotection-bench-to-bedside/)
- [Mortality after Hospitalization with Mild, Moderate, and Severe Hyponatremia](https://scholariq.org/papers/mortality-after-hospitalization-with-mild-moderate-and-severe-hyponatremia/)

## Topic primary papers

Showing 15 of 64.

- [Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis](https://scholariq.org/papers/cardiovascular-and-kidney-outcomes-with-finerenone-in-patients-with-type-2/)
- [Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors](https://scholariq.org/papers/patiromer-in-patients-with-kidney-disease-and-hyperkalemia-receiving-raas/)
- [The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease](https://scholariq.org/papers/the-frequency-of-hyperkalemia-and-its-significance-in-chronic-kidney-disease/)
- [Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/potassium-homeostasis-and-management-of-dyskalemia-in-kidney-diseases/)
- [Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial](https://scholariq.org/papers/evaluation-of-the-efficacy-and-safety-of-rly5016-a-polymeric-potassium-binder-in/)
- [Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease](https://scholariq.org/papers/effect-of-patiromer-on-serum-potassium-level-in-patients-with-hyperkalemia-and/)
- [Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia](https://scholariq.org/papers/effect-of-sodium-zirconium-cyclosilicate-on-potassium-lowering-for-28-days-among/)
- [Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes](https://scholariq.org/papers/association-of-serum-potassium-with-all-cause-mortality-in-patients-with-and/)
- [The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension](https://scholariq.org/papers/the-calcineurin-inhibitor-tacrolimus-activates-the-renal-sodium-chloride/)
- [Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/patiromer-versus-placebo-to-enable-spironolactone-use-in-patients-with-resistant/)
- [Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis](https://scholariq.org/papers/serum-potassium-and-adverse-outcomes-across-the-range-of-kidney-function-a-ckd/)
- [Gastrointestinal Adverse Events with Sodium Polystyrene Sulfonate (Kayexalate) Use: A Systematic Review](https://scholariq.org/papers/gastrointestinal-adverse-events-with-sodium-polystyrene-sulfonate-kayexalate-use/)
- [Ion-Exchange Resins for the Treatment of Hyperkalemia](https://scholariq.org/papers/ion-exchange-resins-for-the-treatment-of-hyperkalemia/)
- [Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function](https://scholariq.org/papers/safety-and-efficacy-of-eplerenone-in-patients-at-high-risk-for-hyperkalemia-and/)
- [ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure](https://scholariq.org/papers/ace-inhibition-or-angiotensin-receptor-blockade-impact-on-potassium-in-renal/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.